Absci Q3 2024 Earnings Report $3.07 -0.30 (-8.90%) As of 01/7/2025 04:00 PM Eastern Earnings HistoryForecast Absci EPS ResultsActual EPS-$0.24Consensus EPS -$0.19Beat/MissMissed by -$0.05One Year Ago EPS-$0.24Absci Revenue ResultsActual Revenue$1.70 millionExpected Revenue$1.77 millionBeat/MissMissed by -$70.00 thousandYoY Revenue GrowthN/AAbsci Announcement DetailsQuarterQ3 2024Date11/12/2024TimeBefore Market OpensConference Call ResourcesConference CallConference Call TranscriptABSI Earnings History Elon’s #1 AI Stock” SET TO SOAR (Ad)Forget ChatGPT! Because Elon Musk's AI promises to be 100x more powerful.Get all the details here >>> Absci Earnings HeadlinesAbsci and AMD Announce Collaboration and Strategic Investment to Accelerate the Future of AI Drug DiscoveryJanuary 8 at 7:00 AM | globenewswire.comAbsci and Invetx Partner to Develop AI-Powered Half-Life Extension Platform for Animal HealthJanuary 7 at 5:48 PM | msn.comliberals FOOLED by Elon’s shocking surpriseElon Musk and Donald Trump fooled everyone. They said it was to “save free speech”... Or “fix what the liberals broke”... But it turns out that was all just a smokescreen to hide the TRUTH…January 8, 2025 | StocksToTrade (Ad)Absci, Invetx partner to bring AI drug creation platform to animal healthJanuary 7 at 12:53 AM | markets.businessinsider.comAbsci and Invetx Partner to Bring Generative AI Drug Creation Platform to Animal HealthJanuary 6 at 8:00 AM | globenewswire.comAbsci to Participate in the 43rd Annual J.P. Morgan Healthcare ConferenceJanuary 2, 2025 | markets.businessinsider.comSee More Absci Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Absci? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Absci and other key companies, straight to your email. Email Address About AbsciAbsci (NASDAQ:ABSI) operates as a data-first generative artificial intelligence (AI) drug creation company in the United States. The company combines AI with scalable wet lab technologies to create biologics for patients. Its integrated drug creation platform is designed to improve upon traditional biologic drug discovery by using AI to simultaneously optimize multiple drug characteristics that may be important to development and therapeutic benefit. The company was founded in 2011 and is headquartered in Vancouver, Washington.View Absci ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles S&P 500 Earnings Set to Shine: January's Critical Market TestCiena Rebounds: AI and Strong Guidance Drive Post-Earnings SurgeHistory Hints at a Rebound for Toll Brothers After EarningsAlibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead?Apple Earnings - When Really Good Just Isn’t Good Enough Upcoming Earnings Schlumberger (1/17/2025)Procter & Gamble (1/22/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
